Paradigm Asset Management’s Myriad Genetics MYGN Stock Holding History

Paradigm Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-450	Closed	-$13.8K	–	734
2016 Q2	$13.8K	Hold	450	–	–	﹤0.01%	755
2016 Q1	$16.8K	Sell	450 -950	-68%	-$35.8K	﹤0.01%	761
2015 Q4	$60.4K	Sell	1,400 -9,600	-87%	-$406K	0.01%	599
2015 Q3	$412K	Sell	11,000 -50	-0.5%	-$1.77K	0.05%	318
2015 Q2	$376K	Hold	11,050	–	–	0.04%	390
2015 Q1	$391K	Hold	11,050	–	–	0.04%	382
2014 Q4	$376K	Hold	11,050	–	–	0.05%	377
2014 Q3	$426K	Buy	+11,050	New	+$412K	0.06%	329

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paradigm Asset Management's MYGN Position: Q3 2016 in Review

Paradigm Asset Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 450 shares — an estimated $13.8K sold.

Paradigm Asset Management first reported a position in MYGN in Q3 2014 and held it in 8 quarters. The position peaked at $426K in Q3 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Paradigm Asset Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Paradigm Asset Management sold 450 Myriad Genetics shares in Q3 2016, an estimated $13.8K.
Paradigm Asset Management first reported a position in Myriad Genetics in Q3 2014 and held it in 8 quarters.
Paradigm Asset Management's Myriad Genetics position peaked at $426K in Q3 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Paradigm Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.